ARGX
FBRX
The biotech lottery ticket just hit the jackpot
Forte Biosciences is suddenly the hottest name in premarket land, with shares blasting higher after argenx SE said it plans to acquire the company for $77 per share in cash. That price tag puts the deal value at about $2.2 billion — a tidy premium if you were holding FBRX and refreshing your brokerage app like it owes you money.
Why this matters
For Forte shareholders, the market is no longer pricing a distant dream of future biotech glory. It’s pricing a very real cash-out, and that usually means the stock trades like a deal-closing puzzle instead of a science experiment.
For argenx, the move suggests it’s willing to pay up for pipeline expansion rather than build everything the slow, painful, and very expensive way from scratch. In biotech, that’s often the grown-up version of “fine, I’ll just buy the thing.”
The other stuff in the article
The piece is also stuffed with a grab bag of other premarket movers — the usual roller-coaster crew of small caps, shelf-offering losers, and yesterday’s momentum chasers. Helpful for traders who like chaos, less helpful for people trying to build a coherent thesis before coffee.
Big picture: this is a classic takeover pop. If the deal closes, Forte’s upside gets pinned near the offer price, and the real question shifts from “will it run?” to “will regulators and shareholders let the wedding happen?”